A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC) [EXTENSION OF 700195808]
Latest Information Update: 08 Jul 2019
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Adverse reactions; Registrational
- Acronyms KODIAC-07
- Sponsors AstraZeneca
- 24 Jun 2016 Results of pooled analysis of three phase III studies (KODIAC 4, KODIAC 5 and KODIAC 7) published in the Advances in Therapy
- 16 Sep 2014 Naloxegol was approved in the US for the treatment of opioid-induced constipation, based on data from this and other trials in the phase III KODIAC programme.
- 10 Apr 2013 New trial record